Suven Life Sciences: Should You Buy, Hold, or Sell Right Now?
- September 4, 2026
- Posted by: Kunal Singla
- Category: Market
Suven Life Sciences share price Rs 378.35 (NSE), roughly flat today. 52-week range Rs 124.11 to Rs 403.35. Q1 FY27 net loss widened to Rs 127.61 crore on tiny revenue.
Quick Answer
Suven Life Sciences Ltd share price is trading around Rs 378, close to its 52-week high of Rs 403.35 and more than triple its 52-week low of Rs 124.11. This is a striking disconnect: Q1 FY27 revenue was just Rs 11.09 crore, a tiny figure relative to the company’s Rs 10,670 crore market capitalisation, while the net loss widened to Rs 127.61 crore from Rs 51.52 crore a year earlier, a clearly worsening trend across four consecutive quarters. The stock’s dramatic rally despite accelerating losses on minimal revenue is a pattern that calls for real caution, and investors should understand this is a speculative situation rather than one supported by conventional fundamentals.
Suven Life Sciences share price has more than tripled from its 52-week low of Rs 124.11, trading near Rs 378 on the NSE, close to its 52-week high of Rs 403.35. Given that this rally has occurred alongside widening losses on very small revenue, this article looks carefully and plainly at whether Suven Life Sciences is a stock to buy on this momentum, a hold, or a sell given the clear disconnect from fundamentals.
This Suven Life Sciences stock analysis presents the Q1 FY27 numbers plainly, highlights the disconnect between the stock’s rally and its financial performance, and walks through valuation, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Suven Life Sciences
Keep this backdrop in mind when reading the rest of this Suven Life Sciences share price review. Before deciding on Suven Life Sciences share price, it helps to understand the underlying business. Suven Life Sciences Ltd. is a pharmaceutical research and development company with a very small current revenue base relative to its market capitalisation, reflecting an early-stage or transitional pharma R&D business model where near-term commercial revenue has not yet materialised at scale.
With quarterly revenue in the range of just a few crore against losses now exceeding Rs 100 crore per quarter, the company’s business fundamentals do not currently support its market valuation through conventional metrics, and investors should understand that the stock’s price action appears to be driven by factors other than reported financial performance.
Suven Life Sciences Share Price Today: Key Levels
The table below summarises where Suven Life Sciences share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Suven Life Sciences CMP (NSE) | Rs 378.35 |
| Suven Life Sciences CMP (BSE) | Rs 377.60 |
| 52-Week High | Rs 403.35 |
| 52-Week Low | Rs 124.11 |
| Market Capitalisation | Approximately Rs 10,670 crore |
Suven Life Sciences share price has more than tripled from its 52-week low, a rally that stands in stark contrast to the company’s widening losses on very small revenue, a disconnect investors should weigh carefully.
Check the Univest Screener for Live Stock Data
Suven Life Sciences Financial Performance
Track this line item closely if you are following Suven Life Sciences share price closely. The Suven Life Sciences share price trend is closely tied to how these numbers evolve each quarter. Suven Life Sciences reported Q1 FY27 (June 2026 quarter) revenue of just Rs 11.09 crore, with a net loss of Rs 127.61 crore, wider than the Rs 51.52 crore loss in the same quarter a year earlier. This continued a clear worsening trend across the past four quarters, with losses widening from Rs 51.52 crore through Rs 77.31 crore, Rs 101.92 crore, and now Rs 127.61 crore, with only a brief narrower loss of Rs 45.6 crore in the March 2026 quarter.
For the full year FY26, the company reported revenue of Rs 21.04 crore against a net loss of Rs 276.34 crore, wider than the Rs 160.75 crore loss in FY25 on revenue of Rs 17.55 crore, confirming that both revenue remains minimal and losses have been accelerating, not a pattern typically associated with a rapidly appreciating stock.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 11.09 crore | Net loss Rs 127.61 crore | Loss widened sharply from Rs 51.52 crore YoY on minimal revenue |
| FY26 (full year) | Rs 21.04 crore | Net loss Rs 276.34 crore | Loss widened from Rs 160.75 crore in FY25 |
Valuation Check: Is Suven Life Sciences Share Price Expensive?
It is one of the clearest signals available on Suven Life Sciences share price today. Any view on Suven Life Sciences share price should start from these valuation multiples. Given Suven Life Sciences’ continued and widening net losses, with a negative trailing EPS of Rs -12.47, the price to earnings ratio is not meaningful here. Return on equity stands at negative 46.73 percent, reflecting the scale of losses relative to the company’s equity base.
The price to book ratio stands at a very rich 15.58 times despite the company being deeply loss-making on minimal revenue, an unusual combination that suggests the stock’s valuation is not currently anchored to conventional financial fundamentals, whether due to speculative trading interest, corporate action expectations, or other factors not reflected in the reported numbers.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Suven Life Sciences share price. Suven Life Sciences share price has more than tripled from its 52-week low of Rs 124.11, trading near its 52-week high of Rs 403.35. A rally of this magnitude occurring alongside accelerating quarterly losses on minimal revenue is a significant divergence from what fundamentals would typically support, and investors should treat this price action with considerable caution rather than assuming it reflects improving business prospects.
Trading volumes have been light in recent sessions, so investors should watch closely for any company disclosures that might explain the sustained rally, rather than assuming the current price reflects the underlying loss-making business.
Download the Univest iOS App or Univest Android App to track Suven Life Sciences’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Suven Life Sciences share price more than headline news on some sessions. Suven Life Sciences is a pharmaceutical research and development company with a currently very small commercial revenue base. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Suven Life Sciences
- Pharma R&D asset base: As a pharmaceutical research company, Suven Life Sciences holds intellectual property and R&D capabilities that could theoretically hold future value if successfully commercialised.
- Sustained investor interest despite losses: The stock’s more than tripling from its 52-week low, despite widening losses, indicates some market participants see value or catalysts not reflected in current financials.
- Low financial leverage: A debt to equity ratio of just 0.03 means the company is not burdened by significant debt obligations despite its losses.
- Potential for future pipeline monetisation: As with other early-stage pharma R&D companies, successful licensing or commercialisation of pipeline assets could meaningfully change the company’s financial trajectory, though this remains speculative.
Risks and Factors to Watch
- Accelerating losses on minimal revenue: Quarterly losses have widened for three of the past four quarters against revenue of just a few crore, a clearly concerning trend for the underlying business.
- Stock price disconnected from fundamentals: The more than tripling of the share price alongside worsening financial performance represents a significant divergence that carries real risk of a sharp correction if sentiment shifts.
- Very rich valuation on conventional metrics: A price to book ratio of 15.58 times for a deeply loss-making company with minimal revenue is difficult to justify through standard fundamental analysis.
- Limited revenue visibility: With quarterly revenue in the low single-digit crores, the company has not yet demonstrated a clear path to meaningful commercial revenue.
Suven Life Sciences Share Price Target: What the Data Suggests
Until then, Suven Life Sciences share price remains best tracked through live, verified data rather than a single fixed number. Given Suven Life Sciences’ widening losses, minimal revenue, and valuation disconnected from conventional fundamentals, no reliable analyst price target framework applies to this stock at this time, and any such figures should be treated with significant skepticism.
Investors considering this stock should track the Univest Screener for the latest disclosures and should consult a SEBI-registered investment adviser given the highly speculative nature of the current price action relative to reported financials.
Suven Life Sciences: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Suven Life Sciences share price right now. The Suven Life Sciences buy or sell decision requires weighing a stock price that has moved sharply against a business whose fundamentals have moved in the opposite direction.
The case for buying: Only risk-tolerant investors who specifically understand speculative pharma R&D situations, and who have independently verified reasons for the rally beyond what is reflected in reported financials, may consider a position.
The case for holding: Existing shareholders who already accept this risk profile may choose to continue monitoring for any company disclosures that clarify the situation.
The case for waiting: Most investors, particularly those seeking conventional fundamentals-based investments, would reasonably prefer to avoid this stock given the clear disconnect between price action and widening losses.
This is a truly high-risk, speculative situation, so any decision here should be made only after consulting a SEBI-registered investment adviser.
Conclusion
Suven Life Sciences share price has more than tripled from its 52-week low even as quarterly losses have widened sharply on minimal revenue, a significant disconnect between price action and reported fundamentals that investors should approach with real caution. This is a speculative, high-risk stock rather than a conventional investment. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Suven Life Sciences a good stock to buy right now?
Ans. Suven Life Sciences share price has more than tripled from its 52-week low even as Q1 FY27 losses widened to Rs 127.61 crore on just Rs 11.09 crore of revenue, a clear disconnect between price action and fundamentals. This is a high-risk, speculative stock suitable only for risk-tolerant investors.
Q2. Why has Suven Life Sciences share price risen despite widening losses?
Ans. Suven Life Sciences share price has more than tripled from its 52-week low despite widening quarterly losses on minimal revenue, and available public data does not identify a clear fundamental catalyst for this rally, suggesting the price action is currently disconnected from reported financial performance.
Q3. What is the Suven Life Sciences share price today?
Ans. Suven Life Sciences share price is trading around Rs 378 on the NSE, close to its 52-week high of Rs 403.35. The stock’s 52-week low is Rs 124.11.
Q4. What is the Suven Life Sciences share price target?
Ans. Given Suven Life Sciences’ widening losses and valuation disconnected from conventional fundamentals, no reliable analyst price target framework applies to this stock. Investors should consult a SEBI-registered adviser given the highly speculative nature involved.
Q5. Is Suven Life Sciences profitable?
Ans. No, Suven Life Sciences continues to report widening losses, including Rs 127.61 crore in Q1 FY27 on just Rs 11.09 crore of revenue, a clearly worsening trend that has persisted across most of the past four quarters.
Q6. What does Suven Life Sciences do?
Ans. Suven Life Sciences is a pharmaceutical research and development company with a currently very small commercial revenue base, reflecting an early-stage or transitional pharma R&D business model.
